INTRODUCTION
============

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance occurring in or first recognizable during pregnancy. GDM is regarded as a complication of pregnancy \[[@B1]\]. Biochemical abnormalities including higher fasting glucose, greater insulin resistance, dyslipidemia (higher triglycerides and lower levels of high-density lipoprotein (HDL) cholesterol), and increased inflammatory biomarkers such as C-reactive protein (CRP) can be observed in GDM patients \[[@B2]\]. Approximately 3%-8% of all pregnancies in the USA are affected by GDM, but its global.

Prevalence varies depending on the population studied and GDM diagnostic criteria used. Worldwide, GDM prevalence varies from 1% to 14% of all pregnancies. GDM affects 7% of pregnant women in Iran \[[@B3]\].

GDM has serious implications on maternal, fetal, and neonatal well-being \[[@B4]\]. Among mothers, it is associated with preeclampsia, higher rates of cesarean section, and increased long-term risks for development of metabolic syndrome and type 2 diabetes mellitus \[[@B5]\]. GDM is also involved in fetal morbidity and mortality \[[@B3]\] from hyperglycemia, hyperinsulinemia, hyperlipidemia, endothelial cell dysfunction \[[@B6]\], and heart dysfunction \[[@B7]\]). In addition, GDM increases the risks of adverse fetal outcomes including macrosomia, neonatal hypoglycemia, infant respiratory distress syndrome, shoulder dystocia, intrauterine growth retardation \[[@B8]\], birth trauma, and hyperbilirubinemia \[[@B9]\]. A systematic review and meta-analysis showed an increased risk of later-life obesity and glucose intolerance in the offspring of mothers with GDM \[[@B5]\].

Certain factors may indicate an increased risk of GDM, including high maternal age, ethnicity, obesity, prior history of GDM, and a family history of type 2 diabetes \[[@B5]\]. Recently, poor vitamin D status was also proposed as a contributor to increased GDM risk \[[@B3][@B4][@B5][@B10][@B11][@B12]\].

Vitamin D, a steroid hormone, is present in animal-based foods and mainly generated from 7-dehydrocholesterol in a sunlight-induced pathway in the skin \[[@B12]\]. Vitamin D has classical effects on calcium homeostasis and bone mineralization. In addition to these classical processes, vitamin D is involved in many other processes, including insulin secretion, cellular proliferation and differentiation, and modulation of immune function \[[@B13]\].

Poor vitamin D status during pregnancy increases risks for infectious diseases, cesarean delivery, preeclampsia, maternal insulin resistance, preterm birth, low birth weight, skeletal abnormalities, and developmental disorders \[[@B14]\]. The prevalence of vitamin D deficiency, defined as 25-hydroxyvitamin D concentrations \< 10 ng/ml (25 nmol/l), varies from 18% to 89.5% during pregnancy, depending on the region and the types of clothing usually worn by women. Vitamin D deficiency has been reported in 80% of pregnant Iranian women \[[@B15]\].

Pregnant women are at high risk for vitamin D deficiency, leading to a nearly twofold increased risk of GDM \[[@B3][@B4][@B16]\], by factors regulating the production of vitamin D in the skin, including skin pigmentation, skin covered by clothes, season, aging, latitude, sunscreen use, and air pollution \[[@B5][@B14]\], and by factors that affect its absorption or metabolism \[[@B5][@B14]\], such as obesity \[[@B15]\] and fetal development \[[@B17]\].

Studies assessing the effects of vitamin D supplementation on the metabolic features of diabetes patients have reported controversial outcomes. In a study conducted by Talaei et al., vitamin D~3~ supplementation (50,000 IU/week) for 8 weeks resulted in significantly decreased serum insulin concentration and homeostasis model assessment-insulin resistance (HOMA-IR) in type 2 diabetes patients \[[@B18]\]. Asemi et al. showed that vitamin D supplementation, with administration of 50,000 IU vitamin D~3~ for 21 days over 6 weeks, had beneficial effects for GDM patients, including improvements in glycemic, total cholesterol, and LDL cholesterol concentrations, but had no effects on inflammation \[[@B17]\]. However, in a study conducted by Mozaffari-Khosravi, a single postpartum injection of 300,000 IU of vitamin D~3~ in mothers with GDM did not affect fasting plasma glucose, HbA1c, or CRP \[[@B19]\].

There is a need to address the scarcity of data on this subject, the controversial results, and the limitations of the aforementioned studies, including low sample sizes and low doses of vitamin D \[[@B17]\]. Therefore, this study was designed to assess the effects of vitamin D supplementation on the metabolic profiles and hs-CRP statuses of pregnant women with GDM.

SUBJECTS AND METHODS
====================

Study participants
------------------

GDM patients were recruited from Al-Zahra Hospital, the academic outpatient center of the Tabriz University of Medical Sciences, Tabriz, Iran. Using a type I error of 5% (a = 0.05), type II error of 20% (b = 0.20, power = 80%), HbA1c concentration as a key factor, and 20% attrition during the study period, it was calculated that 36 subjects would be required for each study condition \[[@B20]\]. The following inclusion criteria were used:

\- Diagnosis of GDM: Pregnant women without a prior diagnosis of glucose intolerance in the first trimester were asked to participate in a 75-g OGTT at 24-28 weeks of gestation. Diagnosis of GDM was based on the International Association of Diabetes and Pregnancy Study Groups criteria. Individuals whose plasma glucose met one or more values in the following criteria were considered to have GDM: fasting plasma glucose, ≥ 92 mg/dl; 1 h, ≥ 180 mg/dl; 2 h, ≥ 153 mg/dl \[[@B1][@B21]\].

\- Age between 15-45 years.

\- Gestational age between 24-28 weeks.

The exclusion criteria were presence of thyroid or parathyroid disorder, kidney or liver diseases, cardiovascular disease, or hypertension, taking vitamin D supplements within 6 months prior to the study, and smoking. Of 230 GDM patients, 76 patients met the inclusion and exclusion criteria, and were selected for the study. The patients were randomly assigned to the vitamin D supplement (n = 38) or placebo (n = 38) conditions, while considering pre-pregnancy weight, and gestational diabetes management method (diet therapy, oral hypoglycemic agents, and insulin therapy). Random assignment was performed using random computer-generated numbers. A trained midwife conducted the randomized allocation sequence and assigned participants to the groups. The study protocol was accepted by the ethics committee of the Tabriz University of Medical Sciences. The IRB approval number of the research was 5/97/1160, 1392/4/30. All subjects provided written informed consent prior to participation. The trial was registered at the Iranian website ([www.irct.ir](http://www.irct.ir)) for the registration of clinical trials as IRCT201306253140N11.

Study design
------------

The study was conducted using a randomized, placebo-controlled, double-blinded approach. The intervention ran from July 2013 through September 2014. Subjects were selected during the summer and spring; therefore, seasonal variation of ultraviolet radiation was deemed not to be a confounding factor.

Participants were advised to maintain their routine diets and lifestyle parameters, including levels of sunlight exposure and physical activity, which could affect vitamin D levels and metabolic factors.

Demographic data and pre-pregnancy weight were collected by interview. Weight (to the nearest 0.1 kg) and height (to the nearest 0.1 cm) were measured in a standard position using a scale (Seca) and an unstretched measuring tape. Body mass index (BMI) was calculated as weight (kg) divided by the square of the height (m).

The dietary intakes of patients were assessed by a 3-day, 24-hour dietary recall before and after the study (2 weekdays, 1 weekend day). Nutritionist IV software, with modifications for Iranian foods, was used for the calculations of average daily nutrient intake (version 3.5.2, First DataBank; Hearst Corp, San Bruno, CA, USA).

Participants in the vitamin D group received oral capsules containing 50,000 IU vitamin D~3~ (D-Vitin50000; Zahravi Pharm Co., Iran), once every 2 weeks for 2 months, for a total of 4 capsules. Those in the placebo group received placeboscomposed of paraffin oil (Dana Pharm Co., Iran) using the same schedule, for a total of 4 placebos. Therefore, the vitamin D group received a total dose of 200,000 IU vitamin D~3~. The safety of this dose in pregnant women was demonstrated in previous studies \[[@B22][@B23][@B24]\].

All features of the placebo and vitamin D~3~ capsules were identical. Participants were followed up with a telephone call every 2 weeks to ensure adherence. Participants were asked to take their vitamin D or placebo capsules after a meal with water. All subjects consumed 400 micrograms/day of folic acid from the beginning of pregnancy and 60 mg/day of ferrous sulfate from the second trimester, on the basis of self-reported data, in accordance with the Iranian Ministry of Health guidelines for pregnant women.

Biochemical analysis
--------------------

Blood samples (5 ml) were obtained after 12 h of overnight fasting at baseline and after the 8-week intervention. The samples were divided into two parts, one aliquot, which was poured for measurement of HbA1c in heparinized tubes, and the remaining amount was centrifuged immediately (Hettich; ROTOFIX 32 A) at 4,000 rpm for 5-10 min to separate the serum. Both serum and blood samples were stored at -70℃ until assayed at the Tabriz University of Medical Sciences Reference Laboratory.

A chemiluminescence immunoassay method was used to determine serum 25- hydroxyvitamin D concentrations (DiaSorin, Stillwater, USA), and insulin levels (DiaSorin, Saluggia, Italy). The fasting plasma glucose level was measured using a spectrophotometric method using a Hitachi Automatic Analyzer 911 (Pars Azmun kit; Hitachi, Tokyo, Japan). A CERA-STAT kit was used for measurement of HbA1c. The HOMA-IR method \[fasting insulin (mU/l) × fasting glucose (mg/dl)/405\] was used for calculation of insulin resistance \[[@B25]\]. An enzymatic method was utilized to determine serum total cholesterol, triglyceride, and LDL- and HDL cholesterol concentrations (Pars Azmun kit). The hs-CRP level was measured using the immunoturbidimetry method (Bio system kit).

Biochemical measurements were performed in a blinded fashion in duplicate, evaluating paired pre- and post-intervention samples at the same time, in the same analytic run, and in a random order to reduce systematic error and interassay variability.

Statistical analysis
--------------------

The Kolmogorov-Smirnov test was used to examine the normal distribution of variables. Mean ± SD or median (IQR) was used for the population characteristics. For normally distributed data, an independent samples Student\'s t-test was performed for determination of basic differences between 2 groups, and a paired t-test to determine differences in each group before and after the intervention.

The Mann-Whitney U test and the Wilcoxon paired rank test were used for nonparametric distributions. To assess the effects of vitamin D supplementation on biochemical parameters between the 2 groups after the intervention, ANCOVA was used by adjusting for the baseline measurements and covariates, including: GDM duration, GDM management method, type and dosage of drugs or insulin, baseline metabolic parameters, age, pre-pregnancy weight, weight gain, and energy and other macronutrient intake (Carbohydrate, Fat, and Protein). Data analysis was performed using SPSS version 22 (SPSS Inc., Chicago, IL, USA). Differences were considered significant at a *P*-value ≤ 0.05.

RESULTS
=======

Baseline characteristics
------------------------

Of the 76 participants, 72 completed the trial (vitamin D group, n = 36; placebo group, n = 36). No side effects from supplementation were reported in either sample group. Four patients who did not consume all of the capsules were excluded from the study. The details of the study design are illustrated in [Fig. 1](#F1){ref-type="fig"}.

The mean ± standard deviation for age, pre-pregnancy weight, pre-pregnancy BMI, and serum 25-hydroxyvitamin D levels of the 72 patients were 31.88 ± 4.00 years, 74.72 ± 10.49 kg, 28.94 ± 3.79 kg/m^2^, and 11.3 ± 6.25 ng/ml, respectively. The baseline details for each group are shown in [Table 1](#T1){ref-type="table"}.

The types of drugs used (metformin) and insulin (NovoRapid, Lantus and NPH) used were similar in both groups. None of the participants showed changes in their disease management methods or dosages during the study. Baseline and post-intervention means of sun exposure duration did not show significant change during the study.

Dietary intakes before and after the intervention period
--------------------------------------------------------

No significant differences in dietary intake at baseline, with the exception of calcium intake, were observed between the 2 groups. After the intervention, the vitamin D group showed significant increases in the dietary intake of energy, fat, SFA, MUFA, and vitamin D. However, there were no statistically significant changes in dietary intake within the placebo group.

ANCOVA, adjusted for BMI and baseline values, showed that only phosphorous intake was significantly different between the two groups after the intervention. There were no other significant differences in dietary intake ([Table 2](#T2){ref-type="table"}).

The differences of dietary factors before and after intervention could have affected the metabolic risk factors in the vitamin D intervention group, therefore the effects of energy intake and other macronutrients before and after the intervention were considered in the analysis of metabolic risk factors.

Metabolic profiles and hs-CRP level before and after the intervention period
----------------------------------------------------------------------------

At baseline, 66 patients (93.1%) had 25-hydroxyvitamin D levels less than 20 ng/ml. At the end of the study, 100% of the patients in the vitamin D group had serum 25-hydroxyvitamin D levels higher than 20 ng/ml compared with 3 patients (8.3%) in the placebo group. However, vitamin D supplementation increased serum 25-hydroxyvitamin D concentrations compared to placebo (19.15 (14.15-29.12) vs. -0.40 (-0.82 - 0.30) ng/ml; *P* \< 0.01). Serum 25-hydroxyvitamin D levels ≥ 50 ng/ml were not observed in any patient after vitamin D supplementation.

Vitamin D supplements were associated with a significant decrease in fasting glucose (4.72 ± 13.99 vs. 5.27 ± 9.93 mg/dl; *P* = 0.01) and HbA1c (-0.18%± 0.48% vs. 0.17%± 0.39%; *P* = 0.02). Vitamin D was associated with decreases in serum total cholesterol, triglycerides, and LDL cholesterol, and HDL cholesterol was also increased, but these changes were not significant. Significant increases in the concentrations of total and LDL cholesterol as well as in fasting glucose and HbA1c were observed in the placebo group.

Baseline values of hs-CRP differed significantly between the two groups. Levels of hs-CRP increased significantly in the placebo group, but did not change in the vitamin D group ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

DISCUSSION
==========

Pregnant women are at an elevated risk for vitamin D deficiency. Several studies have shown that poor vitamin D status during pregnancy increases risk of GDM \[[@B3][@B4][@B5][@B10][@B11][@B12]\]. High circulating 25-hydroxyvitamin D levels have been linked with reductions in risk for types 1 and 2 diabetes \[[@B15][@B26]\]. A cross-sectional study including 3262 adults reported a significant inverse association between 25-hydroxyvitamin D and individual components of metabolic syndrome \[[@B27]\]. An inverse association between 25-hydroxyvitamin D and glycemic control was also reported in women with GDM \[[@B28][@B29]\].

In the current study, administration of 4 oral doses of cholecalciferol (50,000 IU) to GDM patients during a period of 2 months resulted in significantly improved vitamin D status, compared to placebo. In the placebo group, despite constant intake of vitamin D during the intervention, vitamin D concentrations decreased significantly. Similar significant reductions in serum 25-hydroxyvitamin D levels in the placebo group have been reported in other studies \[[@B19][@B36]\]. Decreases in 25-hydroxyvitamin D level in the placebo group in this study and previous research may be related to rapid fetal development, particularly bone calcification at the end of pregnancy \[[@B17]\].

In the current study, significant reductions in FPG and HbA1c without changes in insulin concentrations or HOMA-IR were observed in the vitamin D group. The results of clinical trials of the effects of vitamin D supplementation on glucose homeostasis have been controversial. Asemi et al. reported that vitamin D~3~ supplementation (two doses of 50,000 IU) during 6 weeks in 52 GDM patients resulted in significantly decreased FPG as well as insulin and HOMA-IR \[[@B17]\]. Similar to our findings, administration of 88,865 IU/week vitamin D for one year in 109 prediabetes and vitamin D hypovitaminosis patients had no effect on HOMA-IR. However, lower HbA1c levels were reported in the vitamin D group \[[@B30]\]. In another study in 46 PCOS patients, taking 20,000 IU/week vitamin D~3~ orally for 24 weeks resulted in significantly decreased FPG without changes in fasting insulin level or HOMA-IR \[[@B31]\]. In studies conducted by Witham et al. \[[@B32]\] and Ryu et al. \[[@B33]\] in type 2 diabetes patients, vitamin D~3~ had no significant effect on HOMA-IR. Ardabili et al. reported that, among 50 PCOS patients with vitamin D deficiency, receiving 3 oral capsules of 50,000 IU D~3~ for 2 months did not result in change of fasting insulin levels or HOMA-IR \[[@B34]\]. In contrast, Mozaffari-Khosravi found that a single postpartum injection of a high dose of vitamin D~3~ (300,000 IU) in women with GDM did not affect fasting glucose, HbA1c, or HOMA-IR \[[@B19]\]. Taking 400 IU/day vitamin D~3~ for 14 weeks showed no alterations on HbA1c for 51 type 2 diabetic patients \[[@B35]\]. In 70 type 2 diabetes patients, insulin and HbA1c levels increased significantly in both groups who received either 0.5 µg/day calcitriol or placebo for 12 weeks \[[@B36]\].

FPG and HbA1c showed a remarkable increase in the placebo group compared to the vitamin D group. Similar significant increases in FPG and HOMA-IR among GDM patients \[[@B19]\], as well as increased HbA1c among type 2 diabetes patients \[[@B36]\], has been reported.

Vitamin D may have beneficial effects on insulin secretion, either directly, by enhancing β-cell biosynthetic activity and accelerating the transformation of pro-insulin to insulin \[[@B37]\], or indirectly, via its role in regulating calcium flux through β-cells. Insulin secretion is a calcium-dependent process; hence, alterations in calcium flux can have adverse effects on β-cell secretory functions \[[@B36]\]. Vitamin D may also have a beneficial effect on insulin action either directly, through stimulating the expression of insulin receptors and activating peroxisome proliferator activated receptors \[[@B38]\], or indirectly, via its role in regulating extracellular and intracellular calcium \[[@B27]\].

In cases of hyperparathyroidism, elevated parathyroid hormone levels and enhanced renin production resulting from hypovitaminosis D can contribute to insulin resistance via the suppression of insulin signaling in adipocytes \[[@B33]\]. Insulin resistance may also be facilitated through the interruption of intracellular glucose transporter translocation by angiotensin II \[[@B37]\].

In this study, improvements in the lipid profiles were observed in the vitamin D group, but these changes were not significant. Similarly, some existing literature on vitamin D and lipids did not identify any effects of vitamin D, even when higher doses and longer durations of treatment were used \[[@B39][@B40][@B41]\]. In contrast with our study, 4000 IU/day vitamin D~3~ for 6 months in 104 postmenopausal women with type 2 diabetes decreased TG levels significantly without affecting the levels of other lipids \[[@B42]\]. In another study among 50 PCOS patients with vitamin D deficiency, administration of three oral capsules of 50,000 IU D~3~ for 2 months resulted in significantly decreased serum TG and TC levels \[[@B43]\]. Remarkable reductions in serum total and LDL cholesterol concentrations were also observed in 54 GDM patients who received 2 doses of 50,000 IU D~3~ for six weeks \[[@B17]\].

In the current study significant increases in total and LDL cholesterol levels and significant decreases in HDL cholesterol were observed within the placebo group, when their post-intervention measurements were compared with baseline. Similar changes were observed among GDM and PCOS patients in other studies \[[@B17][@B43]\].

The vitamin D receptor gene regulates approximately 3% of the human genome, including genes that are crucial for glucose and fat metabolism \[[@B44]\]. A known mechanism that can provide a probable explanation for the favorable effects of vitamin D on serum TG levels is its effect on calcium \[[@B43]\]. In the liver, increased intracellular calcium leads to stimulation of microsomal triglyceride transfer protein, involved in the formation and secretion of VLDL, resulting in decreased serum triglycerides and VLDL cholesterol levels \[[@B45]\].

In our study, although vitamin D concentrations increased in the vitamin D group, hs-CRP level was constant. It is possible that vitamin D may prevent increases in hs-CRP in the supplemented group. A meta-analysis of 10 randomized controlled trials suggested the significantly favorable effects of vitamin D supplementation related to the levels of circulating hs-CRP \[[@B46]\]. However, the results from clinical trials on vitamin D supplementation and its effects on CRP levels have been inconsistent. In agreement with our results, the studies conducted by Sadiya et al. \[[@B47]\] and Yiu et al. \[[@B48]\] with type 2 diabetes patients showed that vitamin D~3~ had no significant effect on CRP levels. In contrast, intake of vitamin D supplements in healthy pregnant women has been linked to significant decreases in serum hs-CRP levels \[[@B49]\]. In another study, hs-CRP levels were significantly increased in overweight and obese subjects who received vitamin D~3~ \[[@B50]\].

In the current study, hs-CRP concentrations increased in the placebo group. Similar changes have been observed in type 2 diabetes patients and healthy pregnant women \[[@B47][@B49]\].

The diverse findings on the effects of vitamin D supplementation on metabolic features and hs-CRP levels could be due to use of low dosages of vitamin D in the studies, short durations of supplementation \[[@B30]\], different characteristics of the subjects such as duration of diabetes or vitamin D status, type of vitamin D used \[[@B34]\], baseline status of vitamin D and metabolic indices \[[@B46]\], and wide ranges of post-intervention serum 25-hydroxyvitamin D concentrations in the vitamin D group \[[@B39]\]. Thus, low baseline 25- hydroxyvitamin D levels (11.3 ± 6.25 ng/ml) in our participants and higher baseline hs-CRP levels in the vitamin D group could explain the null results of our study.

Our study had some limitations, including a short duration and low sample size. In addition, the effects of vitamin D supplementation on PTH, maternal oxidative stress status, or infant health outcomes were not examined.

The strengths of our study were its double-blinded, randomized, controlled design; its use of matched groups in terms of known confounds, including age, pre-pregnancy BMI and sunlight exposure; and its assessment of dietary intakes.

In conclusion, vitamin D~3~ supplementation in GDM patients can have beneficial effects on glycemic status; however, it does not affect lipid profiles or hs-CRP levels. Conduct of additional studies to better clarify the role of vitamin D supplementation in GDM patients will be necessary.

This article was written based on a dataset of MS thesis, registered in Tabriz University of Medical Sciences, Tabriz, Iran (Grant number: 5/97/1160-1392/4/30)

![Flow chart illustrating the recruitment of patients for the study](nrp-10-328-g001){#F1}

###### General characteristics of participants

![](nrp-10-328-i001)

Vitamin D~3~ and placebo group: received four doses of vitamin D~3~ (50,000 IU) or placebo as 1 capsule, once every 2 weeks, respectively.

Values are expressed as mean ± SD.

^\*^ expressed as N (%).

^1)^ Independent samples t-test

^2)^ Based on participants\' measured weights and heights from maternity clinic records.

None of the participants showed changes in their disease management methods or dosages during the study.

###### Dietary characteristics of participants

![](nrp-10-328-i002)

Vitamin D~3~ and placebo group: received four doses of vitamin D~3~ (50,000 IU) or placebo as 1 capsule, once every 2 weeks, respectively.

We used mean ± SD for normally distributed and median (25^th^ and 75^th^ percentiles) for nonparametric distribution data.

^1)^ Baseline characteristics between 2 groups were compared using independent samples t-test for normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. After the intervention period, comparisons were done by ANCOVA adjusted for BMI and baseline values.

^2)^ paired - t-test or Wilcoxon test.

###### Baseline and post-intervention metabolic parameters and hs-CRP levels of participants

![](nrp-10-328-i003)

Vitamin D~3~ and placebo group: received four doses of vitamin D~3~ (50,000 IU) or placebo as 1 capsule, once every 2 weeks, respectively.

We used mean ± SD for normally distributed data and median (25^th^ and 75^th^ percentiles) for nonparametric distribution data.

^1)^ paired t-test or Wilcoxon test.

Glucose = fasting plasma glucose, Insulin = fasting serum insulin, HbA1C = Glycated Hemoglobin, HOMA-IR = homeostasis model assessment-insulin resistance, LDL = low density lipoprotein, HDL = high density lipoprotein, hs-CRP = high sensitive C-reactive protein.

###### Changes in metabolic parameters and hs-CRP levels after 2 months (post-intervention minus baseline)

![](nrp-10-328-i004)

Vitamin D~3~ and placebo group: received four doses of vitamin D~3~ (50,000 IU) or placebo as 1 capsule, once every 2 weeks, respectively.

We used mean ± SD for normally distributed and median (25^th^ and 75^th^ percentiles) for nonparametric distribution data.

^1)^ Data were obtained from ANCOVA, adjusted for GDM duration, method of GDM management, type and dosage of drugs or insulin, and baseline values. Baseline values: baseline metabolic parameters, age, pre-pregnancy weight, weight gain, and energy and other macronutrient intake.

Glucose = fasting plasma glucose, Insulin = fasting serum insulin, HbA1C = Glycated Hemoglobin, HOMA-IR = homeostasis model assessment-insulin resistance, LDL = low density lipoprotein, HDL = high density lipoprotein, hs-CRP = high sensitive C-reactive protein.
